While antibiotics are widely used by doctors to treat common infections, an increasing number of strains of bacterial infections are immune to existing antibiotics. The GAIN Act would provide incentives to increase the commercial value of innovative antibiotic drugs and streamline the regulatory process so that pioneering infectious disease products can reach patients.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Antibiotic-resistant infections are on the rise, causing tens of thousands of deaths each year and leading to $26 billion in extra costs annually to the U.S. healthcare system.
Related Articles on Antibiotic Resistance:
Massachusetts Eye and Ear Infirmary to Study MRSA in 5-Year $11M Study
El Camino Hospital’s CMO Outlines 3-Pronged Strategy for C. Diff
Study: Providers Sometimes Blame Others, Not Themselves, for Overprescribing Antibiotics
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.